Congress Pushes for Federal Study of State Cannabis Laws

Congress Takes a Closer Look at State Cannabis Programs

In a significant step forward for cannabis policy reform, the House Appropriations Committee is expected to approve a report calling on federal agencies to study the "adequacy" of state marijuana laws. This move signals a growing bipartisan recognition that the patchwork of state cannabis regulations requires closer federal attention — not to override state autonomy, but to better understand how these programs are functioning.

The directive comes at a pivotal moment in American cannabis policy. With 40 states plus the District of Columbia now operating medical cannabis programs, and 24 states plus DC having legalized recreational adult use, the federal government's continued classification of marijuana as a controlled substance increasingly conflicts with the reality on the ground.

What the Federal Study Would Examine

The proposed study would task federal agencies with evaluating how effectively state cannabis programs are operating across several key dimensions. These include public health outcomes, economic impacts, law enforcement challenges, and the interplay between state-legal markets and the persistent illicit market.

Congressional supporters of the measure argue that reliable federal data on state programs has been sorely lacking. While individual states track their own metrics — from tax revenue to arrest statistics — there has been no comprehensive federal assessment comparing outcomes across different regulatory frameworks.

This information gap has real consequences. Lawmakers on both sides of the aisle have made policy arguments based on incomplete or anecdotal evidence, making it difficult to evaluate which regulatory approaches actually deliver the best outcomes for public health and safety.

Bipartisan Momentum Builds

The call for a federal study reflects a broader trend of bipartisan engagement with cannabis policy in 2026. The bipartisan STATES 2.0 Act, introduced in the House, would end the federal prohibition of cannabis and allow states to determine their own policies. Meanwhile, Senators Rand Paul (R-KY), Amy Klobuchar (D-MN), and Joni Ernst (R-IA) have filed a bill to let states and Indian tribes opt out of the upcoming federal ban on hemp-derived THC products set to take effect in November.

Even the White House has shown movement on the issue. President Trump's executive order directing the attorney general to complete the process of moving cannabis from Schedule I to Schedule III of the Controlled Substances Act represents a significant — if incomplete — shift in federal posture. However, progress has been uneven, with reports that the Department of Justice has been slow to implement the rescheduling directive.

Pennsylvania Governor Josh Shapiro marked the 4/20 cannabis holiday by publicly asking lawmakers to send him a legalization bill, while Massachusetts Governor Maura Healey signed legislation doubling the legal possession limit and overhauling the state's Cannabis Control Commission.

The Rescheduling Question Looms Large

The proposed federal study cannot be separated from the larger rescheduling debate. Moving cannabis from Schedule I — the most restrictive category, reserved for substances with "no currently accepted medical use" — to Schedule III would represent a seismic shift for the industry.

Schedule III classification would bring immediate tax relief for cannabis businesses, which currently cannot claim standard business deductions under Section 280E of the Internal Revenue Code. It would also open the door to more robust federal research, which has been hampered by Schedule I restrictions for decades.

However, rescheduling to Schedule III would not federally legalize marijuana. Cannabis would still be regulated under the Controlled Substances Act, and the gap between federal and state law would persist, albeit in a less severe form.

The FDA's failure to meet its February 2026 deadlines for issuing clarifying guidelines related to cannabis regulations has added uncertainty. Industry stakeholders and state regulators alike are operating without clear federal guidance, creating a regulatory limbo that affects everything from banking access to interstate commerce.

What This Means for the Cannabis Industry

For cannabis businesses, the prospect of a comprehensive federal study is a double-edged sword. On one hand, rigorous data could bolster the case for further reform by demonstrating that state-legal markets can operate safely and generate significant economic benefits. On the other hand, a study that highlights negative outcomes — such as increased youth access or impaired driving rates — could provide ammunition for opponents of legalization.

Industry analysts at ATB Capital Markets have forecast modest but steady growth for the sector, projecting 4 percent revenue growth among multi-state operators in 2026. The combination of potential regulatory changes, decreased competition from market consolidation, and continued expansion into new states provides a cautiously optimistic outlook.

The cannabis retail landscape is also evolving rapidly. Pre-roll products have now surpassed traditional flower as the top-selling category by unit volume, reflecting changing consumer preferences and improved manufacturing capabilities. This product shift has implications for regulation, as different product categories present different challenges for testing, labeling, and quality control.

Countermovement and Resistance

The push for federal study also comes against a backdrop of growing resistance to cannabis legalization in some quarters. Several states have seen efforts to roll back existing legalization through ballot measures. Arizona's Repeal Marijuana Legalization Initiative has been cleared to begin collecting signatures, while a Massachusetts proposal would dismantle the state's regulated recreational market.

These repeal efforts, along with the upcoming federal ban on hemp-derived THC products, suggest that the trajectory of cannabis policy reform is not as linear as it might have seemed a few years ago. The Rockefeller Institute of Government has characterized 2026 as a year of "setbacks, rollbacks, and roadblocks" for cannabis policy.

A comprehensive federal study could help clarify these debates by providing an authoritative evidence base. Whether that evidence ultimately supports expansion or restriction of cannabis access remains to be seen — but the bipartisan agreement that more data is needed represents progress in itself.

Looking Ahead

As Congress moves forward with its call for a federal study of state cannabis laws, the cannabis industry finds itself at a crossroads. The next several months will bring critical decisions on rescheduling, the hemp THC ban, and state-level ballot measures that could reshape the regulatory landscape.

For consumers, patients, and businesses operating in state-legal markets, the message from Congress is cautiously encouraging: the federal government is finally taking a serious, data-driven look at how cannabis legalization is working in practice. The results of that examination will likely shape cannabis policy for years to come, making this a moment worth watching closely for anyone with a stake in the future of legal cannabis in America.

For a more comprehensive breakdown of this directive and what it means for the industry, see: Congress Orders Federal Study of State Cannabis Laws 2026